Semaglutide vs Ozempic: What's the Difference?

Semaglutide is a GLP-1 receptor agonist — a synthetic peptide that mimics the incretin hormone GLP-1 (glucagon-like peptide-1). It was developed by Novo Nordisk and works by binding to GLP-1 receptors in the pancreas, brain, and gut to regulate blood sugar, reduce appetite, and slow gastric emptying.

The molecule itself is a 31-amino acid peptide with a fatty acid side chain that extends its half-life to approximately 7 days, allowing once-weekly dosing. This structural modification is what distinguishes semaglutide from naturally occurring GLP-1, which has a half-life of only 2-3 minutes.

Semaglutide is the active pharmaceutical ingredient (API) — the actual compound responsible for the therapeutic effects. Everything else — the brand name, the delivery device, the formulation — is packaging around this core molecule.

Novo Nordisk markets semaglutide under several brand names, each targeting different conditions and using different delivery methods:

Ozempic — Injectable semaglutide approved for type 2 diabetes management. Available in pre-filled pens with doses of 0.25mg, 0.5mg, 1mg, and 2mg. This was the first widely available semaglutide product and remains the most recognised brand name.

Wegovy — Injectable semaglutide approved specifically for weight management. Higher doses (up to 2.4mg weekly) than Ozempic, with a dosing escalation schedule designed for weight loss rather than blood sugar control.

Rybelsus — Oral semaglutide tablets for type 2 diabetes. Available in 3mg, 7mg, and 14mg doses. The oral formulation uses an absorption enhancer (SNAC) to protect semaglutide from degradation in the stomach.

The key point: All three products contain the same semaglutide molecule. The differences lie in dosing, approved indications, delivery method, and regulatory status. When people say "Ozempic for weight loss," they often mean semaglutide — but Wegovy is the formulation specifically approved for that purpose.

The research peptide market also offers semaglutide, which adds another layer to this distinction:

Pharmaceutical semaglutide (Ozempic/Wegovy): - Manufactured under GMP conditions by Novo Nordisk - Undergone Phase I–III clinical trials with thousands of participants - Regulated by MHRA (UK), EMA (EU), and FDA (US) - Available only by prescription - Pre-filled pen delivery with precise dosing - Costs £150-300+ per month through NHS or private prescription

Research-grade semaglutide: - Synthesised by peptide manufacturing companies - Sold as lyophilised powder "for research purposes only" - Not regulated as a medicine - Requires reconstitution with bacteriostatic water - Purity varies by supplier (check COAs for ≥95% HPLC purity) - Typically £45-80 per 3mg vial

Are they the same molecule? Chemically, yes — if the research-grade version is properly synthesised and verified by mass spectrometry. However, the manufacturing oversight, quality assurance, and regulatory protections differ enormously. A third-party COA showing correct molecular weight and high HPLC purity provides reasonable confidence in identity and quality, but it's not equivalent to the full pharmaceutical quality framework.

For UK consumers navigating this landscape, several practical points matter:

Prescription access: Semaglutide is available on NHS prescription for type 2 diabetes (Ozempic) and, in some cases, for weight management (Wegovy) through specialist weight management services. Private clinics also prescribe semaglutide, typically at higher cost.

Research peptide legality: Research-grade semaglutide is legal to purchase in the UK when sold for research purposes. However, it cannot be legally marketed as a medicine or supplement for human use.

"Ozempic" is not a generic term: Using "Ozempic" to describe any semaglutide product is technically incorrect and can be misleading. If a research peptide supplier labels their product as "Ozempic," that's a red flag — it suggests either trademark infringement or an attempt to imply pharmaceutical equivalence.

Dosing differences matter: Pharmaceutical semaglutide comes in precise, pre-measured doses with clear titration schedules backed by clinical trial data. Research-grade semaglutide requires manual reconstitution and dosing, which introduces potential for measurement errors.

The bottom line: Semaglutide is the molecule; Ozempic and Wegovy are branded pharmaceutical products containing that molecule. Research-grade semaglutide is the same compound produced outside the pharmaceutical regulatory framework. Understanding this distinction helps you make informed decisions about quality, safety, and value.